Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-1697
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-10-17T10:42:49.693970Z
status: published
lens: g_space
sector: health
headline: DIAGNOSTIC ACCURACY OF ARTIFICIAL INTELLIGENCE-ASSISTED MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING FOR THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER
dek: Background: Prostate cancer is one of the leading malignancies among men worldwide.Multiparametric magnetic resonance imaging (mpMRI) has become an essential imaging modality for the detection of clinically significant prostate cancer.Recent advances in artificial intelligence (AI) have shown promising potential in improving the accuracy and consistency of prostate MRI interpretation.Objective: To evaluate the diagnostic accuracy of artificial intelligence-assisted multiparametric magnetic resonance imaging for…
gain_title: In 50 men with suspected prostate cancer, AI-assisted multiparametric MRI detected clinically significant cancer with 91.2% sensitivity and 86.0% overall accuracy against biopsy results.
problem_title: (none)
trace_subject: (none)
gain_reading: In 50 men with suspected prostate cancer, AI-assisted multiparametric MRI detected clinically significant cancer with 91.2% sensitivity and 86.0% overall accuracy against biopsy results.
gain_evidence: The sensitivity, specificity, PPV, NPV, and overall diagnostic accuracy were 91.2%, 75.0%, 88.6%, 80.0%, and 86.0%, respectively.
problem_reading: (none)
problem_evidence: (none)
quick_read: A hospital-based prospective study enrolled 50 men with clinical suspicion of prostate cancer. Each had multiparametric MRI read with AI-assisted software and then underwent prostate biopsy, with histopathology as the reference standard. Cancer was confirmed in 34 patients.

If the performance holds up, AI support could help radiologists find significant cancers more consistently and choose which patients need a biopsy. The sample is small and from a single hospital, and the authors say larger multicentre studies are needed before widespread clinical use.
limitation: The study enrolled only 50 patients, and the authors state that larger multicentre studies are required to validate the findings before widespread clinical implementation.
tag: Evidence-backed gain
key_points: Participants had a mean age of 66.2 years, and 34 of the 50 (68%) had clinically significant prostate cancer on histopathology. | The tool produced 31 true positives, 12 true negatives, 4 false positives and 3 false negatives. | Specificity was 75.0%, positive predictive value 88.6% and negative predictive value 80.0%. | The authors report an area under the ROC curve of 0.89 and a significant association with histopathology (p < 0.001).
rundown: The protocol combined T2-weighted imaging, diffusion-weighted imaging, apparent diffusion coefficient mapping and dynamic contrast-enhanced imaging where indicated. Interpretation was done with AI-assisted software, and every patient went on to biopsy.

Diagnostic performance was judged by sensitivity, specificity, predictive values, overall accuracy and ROC area. The authors conclude that AI can act as a decision-support tool for radiologists by improving lesion detection, reducing interobserver variability and aiding patient selection for biopsy.

The summary reports the cohort's results but does not describe a comparison arm without AI, so the stated benefits for variability and biopsy selection are the authors' interpretation rather than separately shown results.
sources:
- peer_reviewed | International Journal of Drug Delivery Technology | https://doi.org/10.25258/ijddt.16.72s.50 | 2026-10-16
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

5ac2150399e49964fd82ddd30ee1056910b8f3b6dd67a81724450778898be5a6

previous

0000000000000000000000000000000000000000000000000000000000000000